ALK-fused spitzoid neoplasms represent a distinctive group of melanocytic lesions. To date, few studies addressed genetic and chromosomal alterations in these lesions beyond the ALK rearrangements. Our objective was to study genetic alterations, including ALK gene fusions, telomerase reverse transcriptase promoter (TERT-p) mutations, chromosomal copy number changes, and mutations in other genes. We investigated 29 cases of Spitz lesions (11 Spitz nevi and 18 atypical Spitz tumors), all of which were ALK immunopositive. There were 16 female and 13 male patients, with age ranging from 1 to 43 years (mean, 18.4 years). The most common location was the lower extremity. Microscopically, all neoplasms were polypoid or dome shaped with a plexiform, predominantly dermally located proliferation of fusiform to spindled melanocytes with mild to moderate pleomorphism. The break-apart test for ALK was positive in 17 of 19 studied cases. ALK fusions were detected in 23 of 26 analyzable cases by Archer FusionPlex Solid Tumor Kit. In addition to the previously described rearrangements, 3 novel fusions, namely, KANK1-ALK, MYO5A-ALK, and EEF2-ALK, were found. Fluorescence in situ hybridization for copy number changes yielded one case with the loss of RREB1 among 21 studied cases. TERT-p hotspot mutation was found in 1 of 23 lesions. The mutation analysis of 271 cancer-related genes using Human Comprehensive Cancer Panel was performed in 4 cases and identified in each case mutations in several genes with unknown significance, except for a pathogenic variant in the BLM gene. Our study confirms that most ALK fusion spitzoid neoplasms can be classified as atypical Spitz tumors, which occurs in young patients with acral predilection and extends the spectrum of ALK fusions in spitzoid lesions, including 3 hitherto unreported fusions. TERT-p mutations and chromosomal copy number changes involving 6p25 (RRB1), 11q13 (CCND1), 6p23 (MYB), 9p21 (CDKN2A), and 8q24 (MYC) are rare in these lesions. The significance of mutation in other genes remains unknown.

Agel Laboratory Novy Jicin Czech Republic

Bioptical Laboratory Pilsen Czech Republic

Clinical and Transplant Pathology Centre Institute for Clinical and Experimental Medicine Prague Czech Republic

Department of Dermatology University Hospital Zagreb Croatia

Department of Pathology 1st Faculty of Medicine and General University Hospital Charles University Prague Czech Republic; and

Department of Pathology L Pausteur University Hospital Kosice Czech Republic

Department of Pathology Regional Hospital Karlovy Vary Czech Republic

Department of Pathology Regional Hospital Kolin Czech Republic

Department of Pathology University Hospital Brno Czech Republic

Pathology Laboratory Chomutov Chomutov Czech Republic

Sikl's Department of Pathology Medical Faculty in Pilsen Charles University Prague Pilsen Czech Republic

Zobrazit více v PubMed

Weedon D, Little JH. Spindle and epithelioid cell nevi in children and adults. A review of 211 cases of the Spitz nevus. Cancer. 1977;40:217–225.

Requena C, Requena L, Kutzner H, et al. Spitz nevus: a clinicopathological study of 349 cases. Am J Dermatopathol. 2009;31:107–116.

Plaza JA, De Stefano D, Suster S, et al. Intradermal spitz nevi: a rare subtype of spitz nevi analyzed in a clinicopathologic study of 74 cases. Am J Dermatopathol. 2014;36:283–294.

Barnhill RL, Argenyi ZB, From L, et al. Atypical Spitz nevi/tumors: lack of consensus for diagnosis, discrimination from melanoma, and prediction of outcome. Hum Pathol. 1999;30:513–520.

Barnhill RL. The spitzoid lesion: the importance of atypical variants and risk assessment. Am J Dermatopathol. 2006;28:75–83.

Barnhill RL. The Spitzoid lesion: rethinking Spitz tumors, atypical variants, spitzoid melanoma and risk assessment. Mod Pathol. 2006;19(suppl 2):S21–S33.

Spatz A, Calonje E, Handfield-Jones S, et al. Spitz tumors in children: a grading system for risk stratification. Arch Dermatol. 1999;135:282–285.

Gerami P, Cooper C, Bajaj S, et al. Outcomes of atypical spitz tumors with chromosomal copy number aberrations and conventional melanomas in children. Am J Surg Pathol. 2013;37:1387–1394.

Urso C. The atypical Spitz tumor of uncertain biologic potential: a series of 67 patients from a single institution. Cancer. 2010;116:258.

Miteva M, Lazova R. Spitz nevus and atypical spitzoid neoplasm. Semin Cutan Med Surg. 2010;29:165–173.

Zedek DC, McCalmont TH. Spitz nevi, atypical spitzoid neoplasms, and spitzoid melanoma. Clin Lab Med. 2011;31:311–320.

Ludgate MW, Fullen DR, Lee J, et al. The atypical Spitz tumor of uncertain biologic potential: a series of 67 patients from a single institution. Cancer. 2009;115:631–641.

Yeh I, de la Fouchardiere A, Pissaloux D, et al. Clinical, histopathologic, and genomic features of Spitz tumors with ALK fusions. Am J Surg Pathol. 2015;39:581–591.

Busam KJ, Kutzner H, Cerroni L, et al. Clinical and pathologic findings of Spitz nevi and atypical Spitz tumors with ALK fusions. Am J Surg Pathol. 2014;38:925–933.

Wiesner T, He J, Yelensky R, et al. Kinase fusions are frequent in Spitz tumours and spitzoid melanomas. Nat Commun. 2014;5:3116.

Saraggi D, Salmaso R, Zamuner C, et al. Prevalence of ALK gene alterations among the spectrum of plexiform spitzoid lesions. J Am Acad Dermatol. 2018;79:728–735.

Gerami P, Scolyer RA, Xu X, et al. Risk assessment for atypical spitzoid melanocytic neoplasms using FISH to identify chromosomal copy number aberrations. Am J Surg Pathol. 2013;37:676–684.

Gerami P, Li G, Pouryazdanparast P, et al. A highly specific and discriminatory FISH assay for distinguishing between benign and malignant melanocytic neoplasms. Am J Surg Pathol. 2012;36:808–817.

Ferrara G, Misciali C, Brenn T, et al. The impact of molecular morphology techniques on the expert diagnosis in melanocytic skin neoplasms. Int J Surg Pathol. 2013;21:483–492.

Lee CY, Sholl LM, Zhang B, et al. Atypical spitzoid neoplasms in childhood: a molecular and outcome study. Am J Dermatopathol. 2017;39:181–186.

High WA. Detection of genetic aberrations in the assessment and prognosis of melanoma. Dermatol Clin. 2017;35:525–536.

Bastian BC, Wesselmann U, Pinkel D, et al. Molecular cytogenetic analysis of Spitz nevi shows clear differences to melanoma. J Invest Dermatol. 1999;113:1065–1069.

Wiesner T, Kutzner H, Cerroni L, et al. Genomic aberrations in spitzoid melanocytic tumours and their implications for diagnosis, prognosis and therapy. Pathology. 2016;48:113–131.

Rand AJ, Flejter WL, Dowling CA, et al. Atypical ALK-positive Spitz tumors with 9p21 homozygous deletion: report of two cases and review of the literature. J Cutan Pathol. 2018;45:136–140.

Barnhill RL, Flotte TJ, Fleischli M, et al. Cutaneous melanoma and atypical Spitz tumors in childhood. Cancer. 1995;76:1833–1845.

Massi D, De Giorgi V, Mandala M. The complex management of atypical Spitz tumours. Pathology. 2016;48:132–141.

Kiuru M, Jungbluth A, Kutzner H, et al. Spitz tumors: comparison of histological features in relationship to immunohistochemical staining for ALK and NTRK1. Int J Surg Pathol. 2016;24:200–206.

Smith KJ, Barrett TL, Skelton HG III, et al. Spindle cell and epithelioid cell nevi with atypia and metastasis (malignant Spitz nevus). Am J Surg Pathol. 1989;13:931–939.

Lee S, Barnhill RL, Dummer R, et al. TERT promoter mutations are predictive of aggressive clinical behavior in patients with spitzoid melanocytic neoplasms. Sci Rep. 2015;5:11200.

Cerroni L, Barnhill R, Elder D, et al. Melanocytic tumors of uncertain malignant potential: results of a tutorial held at the XXIX Symposium of the International Society of Dermatopathology in Graz. Am J Surg Pathol. 2010;34:314–326.

Yazdan P, Cooper C, Sholl LM, et al. Comparative analysis of atypical spitz tumors with heterozygous versus homozygous 9p21 deletions for clinical outcomes, histomorphology, BRAF mutation, and p16 expression. Am J Surg Pathol. 2014;38:638–645.

Harms PW, Hocker TL, Zhao L, et al. Loss of p16 expression and copy number changes of CDKN2A in a spectrum of spitzoid melanocytic lesions. Hum Pathol. 2016;58:152–160.

Kazakov DV, Kyrpychova L, Martinek P, et al. ALK gene fusions in epithelioid fibrous histiocytoma: a study of 14 cases, with new histopathological findings. Am J Dermatopathol 2018;40:805–814.

Pivovarcikova K, Pitra T, Vanecek T, et al. Comparative study of TERT gene mutation analysis on voided liquid-based urine cytology and paraffin-embedded tumorous tissue. Ann Diagn Pathol. 2016;24:7–10.

van Dongen JJ, Langerak AW, Bruggemann M, et al. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia. 2003;17:2257–2317.

Ward DG, Baxter L, Gordon NS, et al. Multiplex PCR and next generation sequencing for the non-invasive detection of bladder cancer. PLoS One. 2016;11:e0149756.

Lek M, Karczewski KJ, Minikel EV, et al. Analysis of protein-coding genetic variation in 60,706 humans. Nature. 2016;536:285–291.

Landrum MJ, Lee JM, Benson M, et al. ClinVar: improving access to variant interpretations and supporting evidence. Nucleic Acids Res. 2018;46:D1062–D1067.

Shihab HA, Gough J, Cooper DN, et al. Predicting the functional consequences of cancer-associated amino acid substitutions. Bioinformatics. 2013;29:1504–1510.

Adzhubei IA, Schmidt S, Peshkin L, et al. A method and server for predicting damaging missense mutations. Nat Methods. 2010;7:248–249.

Kumar P, Henikoff S, Ng PC. Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. Nat Protoc. 2009;4:1073–1081.

Choi Y, Chan AP. PROVEAN web server: a tool to predict the functional effect of amino acid substitutions and indels. Bioinformatics. 2015;31:2745–2747.

Quan VL, Panah E, Zhang B, et al. The role of gene fusions in melanocytic neoplasms. J Cutan Pathol. 2019;46:878–887.

Perron E, Pissaloux D, Charon Barra C, et al. Melanocytic myxoid spindle cell tumor with ALK rearrangement (MMySTAR): report of 4 cases of a nevus variant with potential diagnostic challenge. Am J Surg Pathol. 2018;42:595–603.

Donati M, Kastnerova L, Martinek P, et al. Spitz tumors with ROS1 fusions: a clinicopathological study of 6 cases, including FISH for chromosomal copy number alterations and mutation analysis using next-generation sequencing. Am J Dermatopathol. 2019;42:92–102.

Hoang MP. Myxoid spitz nevus. J Cutan Pathol. 2003;30:566–568.

Fernandez-Flores A, Riveiro-Falkenbach E, Cassarino DS. Myxoid spitz nevi: report of 6 cases. Am J Dermatopathol. 2018;40:30–35.

Fujimoto M, Togashi Y, Matsuzaki I, et al. A case report of atypical Spitz tumor harboring a novel MLPH-ALK gene fusion with discordant ALK immunohistochemistry results. Hum Pathol. 2018;80:99–103.

Chung CT, Marrano P, Swanson D, et al. Fusion of ALK to the melanophilin gene MLPH in pediatric Spitz nevi. Hum Pathol. 2019;87:57–64.

Suzuki A, Iizuka A, Komiyama M, et al. Identification of melanoma antigens using a serological proteome approach (SERPA). Cancer Genomics Proteomics. 2010;7:17–23.

Gu Y, Zhang M. Upregulation of the Kank1 gene inhibits human lung cancer progression in vitro and in vivo. Oncol Rep. 2018;40:1243–1250.

Kakinuma N, Zhu Y, Wang Y, et al. Kank proteins: structure, functions and diseases. Cell Mol Life Sci. 2009;66:2651–2659.

Yeh I, Tee MK, Botton T, et al. NTRK3 kinase fusions in Spitz tumours. J Pathol. 2016;240:282–290.

Zito Marino F, Rocco G, Morabito A, et al. A new look at the ALK gene in cancer: copy number gain and amplification. Expert Rev Anticancer Ther. 2016;16:493–502.

Scattone A, Catino A, Schirosi L, et al. Discordance between FISH, IHC, and NGS analysis of ALK status in advanced non-small cell lung cancer (NSCLC): a brief report of 7 cases. Transl Oncol. 2019;12:389–395.

Amin SM, Haugh AM, Lee CY, et al. A comparison of morphologic and molecular features of BRAF, ALK, and NTRK1 fusion spitzoid neoplasms. Am J Surg Pathol. 2017;41:491–498.

Wu G, Barnhill RL, Lee S, et al. The landscape of fusion transcripts in spitzoid melanoma and biologically indeterminate spitzoid tumors by RNA sequencing. Mod Pathol. 2016;29:359–369.

Newman S, Fan L, Pribnow A, et al. Clinical genome sequencing uncovers potentially targetable truncations and fusions of MAP3K8 in spitzoid and other melanomas. Nat Med. 2019;25:597–602.

Heidenreich B, Nagore E, Rachakonda PS, et al. Telomerase reverse transcriptase promoter mutations in primary cutaneous melanoma. Nat Commun. 2014;5:3401.

Lazova R, Pornputtapong N, Halaban R, et al. Spitz nevi and Spitzoid melanomas: exome sequencing and comparison with conventional melanocytic nevi and melanomas. Mod Pathol. 2017;30:640–649.

Karow JK, Constantinou A, Li JL, et al. The Bloom's syndrome gene product promotes branch migration of holliday junctions. Proc Natl Acad Sci USA. 2000;97:6504–6508.

Nimonkar AV, Genschel J, Kinoshita E, et al. BLM-DNA2-RPA-MRN and EXO1-BLM-RPA-MRN constitute two DNA end resection machineries for human DNA break repair. Genes Dev. 2011;25:350–362.